Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi
| العنوان: | Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi |
|---|---|
| المؤلفون: | Laura Ballotta, Pier Luigi Zinzani, Stefano Pileri, Riccardo Bruna, Monica Tani, Beatrice Casadei, Valentina Tabanelli, Stefano Volpetti, Stefano Luminari, Paolo Corradini, Elisa Lucchini, Maria Chiara Tisi, Michele Merli, Alessandro Re, Marzia Varettoni, Emanuela Anna Pesce, Francesco Zaja |
| المساهمون: | Ballotta, L., Zinzani, P. L., Pileri, S., Bruna, R., Tani, M., Casadei, B., Tabanelli, V., Volpetti, S., Luminari, S., Corradini, P., Lucchini, E., Tisi, M. C., Merli, M., Re, A., Varettoni, M., Pesce, E. A., Zaja, F., Ballotta L., Zinzani P.L., Pileri S., Bruna R., Tani M., Casadei B., Tabanelli V., Volpetti S., Luminari S., Corradini P., Lucchini E., Tisi M.C., Merli M., Re A., Varettoni M., Pesce E.A., Zaja F. |
| المصدر: | Frontiers in Oncology, Vol 11 (2021) Frontiers in Oncology |
| بيانات النشر: | Frontiers Media S.A., 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | BCL2 inhibition, BCL2 protein, peripheral T-cell lymphoma, relapsed/refractory, venetoclax, Cancer Research, Oncology, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Clinical Trial, RC254-282 |
| الوصف: | Patients with relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL) have a poor prognosis, with an expected survival of less than 1 year using standard salvage therapies. Recent advances in our understanding of the biology of PTCL have led to identifying B-Cell Lymphoma 2 (BCL2) protein as a potential therapeutic target. BLC2 inhibitor venetoclax was investigated in a prospective phase II trial in patients with BCL2-positive R/R PTCL after at least one previous standard line of treatment (NCT03552692). Venetoclax given alone at a dosage of 800 mg/day resulted in one complete response (CR) and two stable diseases (SDs) among 17 enrolled patients. The majority of patients (88.2%) interrupted the treatment due to disease progression. No relationship with BCL2 expression was documented. At a median follow-up of 8 months, two patients are currently still on treatment (one CR and one SD). No case of tumor lysis syndrome was registered. Therefore, venetoclax monotherapy shows activity in a minority of patients whose biological characteristics have not yet been identified.Clinical Trial Registrationwww.clinicaltrials.gov (NCT03552692, EudraCT number 2017-004630-29). |
| وصف الملف: | ELETTRONICO |
| اللغة: | English |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab0cc0a54747de243e3c031a44d2dff4Test https://www.frontiersin.org/articles/10.3389/fonc.2021.789891/fullTest |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....ab0cc0a54747de243e3c031a44d2dff4 |
| قاعدة البيانات: | OpenAIRE |
| الوصف غير متاح. |